Drs. Binder and Puchner contributed equally to this work.
Tumor necrosis factor–inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor–driven model of rheumatoid arthritis†
Version of Record online: 25 FEB 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 65, Issue 3, pages 608–617, March 2013
How to Cite
Binder, N. B., Puchner, A., Niederreiter, B., Hayer, S., Leiss, H., Blüml, S., Kreindl, R., Smolen, J. S. and Redlich, K. (2013), Tumor necrosis factor–inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor–driven model of rheumatoid arthritis. Arthritis & Rheumatism, 65: 608–617. doi: 10.1002/art.37797
This is a publication of the Joint and Bone Center for Diagnosis, Research and Therapy of Musculoskeletal Disorders, Medical University of Vienna.
- Issue online: 25 FEB 2013
- Version of Record online: 25 FEB 2013
- Accepted manuscript online: 28 DEC 2012 11:29AM EST
- Manuscript Accepted: 8 NOV 2012
- Manuscript Received: 15 JAN 2012
- European Community Seventh Framework Programme. Grant Number: project Masterswitch: HEALTH-F2-2008-223404
- Abbott Immunology
Additional Supporting Information may be found in the online version of this article.
|ART_37797_sm_SupplFigure1.tif||605K||Supplementary Figure 1|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.